In June 2021, the United States Food and Drug Administration (FDA) made a landmark decision to approve the Alzheimer’s drug aducanumab (known commercially as Aduhelm). Although we are still waiting to learn whether aducanumab will be granted similar approval for use in the UK, this is the first time a drug has been approved for dementia…
Today is a historic day for dementia research with the US Food and Drug Administration (FDA) announcing the first (conditional) licence of a new drug for Alzheimer’s disease in a generation.
The Pharmaceutical company Biogen plans to file for US marketing approval for aducanumab, an experimental treatment for early Alzheimer’s disease.
Innovative treatments can be life-saving or life-enhancing for patients, their families and carers. Research breakthroughs also drive further scientific discovery, leading to the medicines of tomorrow.
With our survey, developed with academics from the University of Edinburgh, we aim to gather opinions from as many people as possible. This will help us to pick out trends in opinion, and learn whether different groups of people tend to value different things.
Thanks to your support, we are now able to fund a new clinical trial to explore whether a cannabis-based treatment could help.
Non-drug approaches also hold real promise in limiting the devastating effects of dementia.
Although the US and UK health systems are inherently different, this review of the American system is a reminder of the need within our own health system to prepare for new treatments.
We examine the evidence for Coconut Oil as a treatment for Alzheimer’s, and look at the science behind the anecdotal claims.
Findings were reported today from the first phase III anti-tau drug in people with mild-to-moderate Alzheimer’s. The drug, called LMTM, was being tested in a 15-month double-blind, controlled trial in 891 people.